Replies to post #1844 on Enanta Pharmaceuticals Inc (ENTA)

[DewDiligence]

Thanks for posting that excerpt. EDP-297 sounds highly promising.

Inasmuch as finding an effective and well-tolerated dose of EDP-305 looks like a longshot, I think ENTA should redirect the R&D expenditures on EDP-305 to EDP-297, instead of advancing both compounds.